ATCC ATCC Logo 0
A globe made up of blue lines and white dots.

Innovation Challenge 2021

Innovation Challenge Winners 2021

Accelerate Critical Scientific Discovery

Thank you to everyone who participated in the recent ATCC Innovation Challenge! Through this challenge, we called upon innovators throughout the scientific community to submit a proposal of how they are using ATCC products in a novel way in infectious respiratory disease research or COVID-19 research. After receiving numerous submissions, we are pleased to announce the four winners of the challenge below. We’re proud to be a part of the scientific community that is working toward solving the COVID-19 crisis and we look forward to these innovative ideas coming to fruition.

A person sitting in the background with one hand on a computer keyboard and the other hand holding an illustration of a light bulb, with gears, filament and white outline of a human brain with sparks of light connected by lines around it.

Join the next ATCC Innovation Challenge! Sign up to get notified

Sign Up

Congratulations to our winners

Kartik Balachandran, University of Arkansas
This study focuses on the development of a novel nasal-airway-lung organ-on-chip device that mimics upper and lower respiratory tract physiology during viral exposure, enabling critical research on disease pathology and the identification of therapeutic targets for SARS-CoV-2 and other respiratory diseases.

Gopal Iyer, University of Wisconsin Madison
This research seeks to establish the mechanistic framework of the inflammatory response in COVID-19 patients through gender-specific interrogation and to explore the use of hormone antagonists as a potential mechanism of action for dampening the exacerbated inflammatory signal.

Pengda Liu, University of North Carolina at Chapel Hill
This study takes an innovative approach toward COVID-19 treatment and prevention by evaluating the use of casein kinase I (CKI) antagonists in reducing the infection by of coronavirus.

Bocheng Wu, Georgia Institute Of Technology
Attenuation of the immune response and tissue inflammation is the key for treating COVID-19 patients. This research will evaluate the ability of several novel compounds to effectively and safely reduce inflammation during SARS-CoV-2 infection.

Products of interest:

 

Airway Epithelial Cell Basal Medium (ATCC PCS-300-030)

Bronchial Epithelial Cell Growth Kit  (ATCC PCS-300-040)

Fibroblast Basal Medium (ATCC PCS-201-030)

Fibroblast Growth Kit-Low serum  (ATCC PCS-201-041)

NuLi-1 (ATCC CRL-4011)

Primary Bronchial/Tracheal Epithelial Cells (ATCC PCS-300-010)

Primary Bronchial/Tracheal Epithelial Cells; Fibrosis  (ATCC PCS-300-014)

Primary Lung Fibroblast, Normal, Human (HLF) (ATCC PCS-201-013)

Primary Lung Fibroblast; Fibrosis (ATCC PCS-201-020)

Primary Lung Fibroblasts; Asthma (ATCC PCS-201-015)

Primary Bronchial/Tracheal Epithelial Cells; Asthma (ATCC PCS-300-011)

Quantitative Synthetic SARS-CoV [2003] RNA (ATCC VR-3280SD)

Virome Virus Mix  (ATCC MSA-2008)